2 5,862 1, ,366 2 $(250.00) $(750.00)

Transcription

1 MERGENT OTC UNLISTED NEWS REPORTS Tuesday, April 11, 2017 Volume 33 No. 4 NOTICE Items in this issue will be listed online weekly and printed monthly. NEW COMPANY DESCRIPTIONS (For details on individual listings, see the News Section of this - basic issue) Innerscope Advertising Agency Inc NAME CHANGES (For details on individual listings, see the News Section of this issue) ABT Holdings Inc (to Scoobeez Global Inc) Crypto-Services Inc (to Fortune Valley Treasures Inc) Magnum Hunter Resources Corp (DE) (to Blue Ridge Mountain Resources Inc) Receivable Acquisition & Management Corp (to PwrCor Inc) Strongbow Resources Inc (NV) (to Fortem Resources Inc) Zlato Inc (to Vilacto Bio Inc) 024 PHARMA INC Net sales ,079,541 64,708 97,065 Cost of sales ,426 31,820 40,730 Gross profit ,115 32,888 56,335 Selling, general & expenses , ,885 Impairment of assets , Shipping costs , Web design , Advertising & promotion , Wages & salaries , Occupancy costs , Subcontracts Repairs & maintenance , Travel , Meals & entertainment Office & general Professional fees , Printing fee , Vehicle expense Telephone & telecommunications Interest & bank charges Insurance Utilities , expenses , , ,885 operations (464,085) (400,550) Interest income Amortization of debt discount ,886 9,375 Interest expense ,191 51,041 Gain (loss) on valuation of derivative (139,815)... Settlement expense , ,575 (expense) (389,407) (484,946) operations before income taxes ,040 (853,492) (885,496) ,040 (853,492) (885,496) - diluted outstanding ,488,731 per common share - basic per common share - diluted ,862 1, ,862 1, , ,470 2 $(250.00) $(750.00) 2 $(250.00) $(750.00) consultants Reclassified to conform with 2015 presentation; 2 Adjusted for 1-for-25,000 stock split, February 24, 2017; 3 As of October 20, ; 4 Shares increased due to the effect of issuance of common stock and exchange of Class B shares for Class A stock; 5 Approximately Cash , Cash & cash equivalents ,727 Accounts receivable, gross ,021 Less: allowance for doubtful accounts ,483 Accounts receivable, net ,283 2,538 Inventories ,733 Prepaid deposit , current assets ,290 Due from related companies , Total current assets , ,288 Intangible assets ,543 Fixed assets , Total assets , ,831 Accounts payable , Accounts payable & accrued expenses ,115 Advances from shareholder , Due to related parties ,314 Derivative liability ,418 Convertible promissory note payable ,176 Total current liabilities ,794 1,633,023 Derivative liability on long term debt ,647 Convertible promissory note payable ,771 Total liabilities ,779,441 Series A 3% preferred stock ,922 Class A common Stock ,298,695 Class B common stock ,344 Class A common stock subscription ,570 Share capital capital ,617,245 (accumulated deficit) ,034 (15,364,386) equity (deficit) ,035 (1,603,610) 1ST NRG CORP 2014 Natural gas sales ,993 20,561 COPAS Fees ,538 34, Total revenues , ,997 20,561 Transportation/gathering... 34,971 4,975 Lease operating expense , ,816 14,218 Production taxes ,184 1,955 Total cost & expenses , ,971 21,148 Operating margin.... (18,691) (78,974) (587) Management compensation , , ,000 expenses , , ,951 Total expenses , , ,951 operations (501,498) (545,925) (479,538) Depreciation, depletion & accretion ,641 5,710 Intangible drilling costs ,901 61,944 Sale of properties , Cost of properties sold ,030, Gains (loss) of properties (479,891)... Sale of marketable securities ,391 Interest expense , , ,021 (expense) (380,192) (1,181,263) (195,284).... (881,690) (1,727,188) (674,822) - basic ,248,320, , ,880 outstanding ,248,320, , ,880 per share - basic..... $(0.00) $(1.88) $(0.73) Cash ,711 15,532 Accounts receivable , ,997 Marketable securities ,980 7,980 Notes receivable ,400 18,400 Total current assets , ,909 Oil & gas properties ,998,099 2,017,003 Equipment ,492 10,492 Asset retirement obligation ,099 5,005 Total property & equipment, gross ,231,690 2,032,500

2 406 MERGENT OTC UNLISTED NEWS April 11, 2017 Less accumulated depreciation, depletion & accretion ,262 78,262 Net property & equipment ,153,428 1,954,238 Deposit ,000 Restricted cash ,392,762 14,398,762 Total assets ,809,843 16,553,909 Accounts payable , ,293 Accrued management compensation ,670,422 3,182,672 Short term loans payable , ,020 Advances by related parties , ,845 Current portion of lg-term debt ,566,723 4,161,548 Total current liabilities ,613,097 8,766,378 Asset retirement obligation ,769 4,675 Total long-term liabilities ,769 4,675 Total liabilities ,835,866 8,771,053 Series A - issuable Series B - issuable ,000 30,000 Series B - issued Series D - issuable Series E - issuable Preferred stock subscription receivable - unfilled agreements to issue shares (949) (949) Common stock , ,676 Shares to be issued Shares reserved for issuance Additional paid in capital ,832,088 20,816,051 (accumulated deficit) (13,263,566) (11,535,253) Period net income (loss) (881,690) (1,727,188) equity (deficit) As reported by the Company 3DICON CORP Earnings, 9 mos. to Sep 30(Consol. $): 1 6,973,977 7,782,856 Total revenues ,122 Cost & expenses , ,832 Net income (349,426) (733,710) Earnings common share Primary $ $(0.00) Fully Diluted $ $(0.00) Common Shares: Full Diluted ,022,810 Year-end ,481,754,5331,042,491, PEA INTERNATIONAL INC 2014 Revenues ,416,672 8,107,541 10,293,180 Cost of revenues ,197,370 4,019,514 4,654,715 Gross profit ,219,302 4,088,027 5,638,465 Depreciation & amortization , , ,594 Selling, general & expenses ,288,373 3,734,187 2,715,316 expenses ,860,693 4,096,899 2,886,910 operations ,358,609 (8,872) 2,751,555 Gain on debt extinguishment , Other expenses (16,149) 6, Legal settlement ,500, Interest expense ,107 45, ,515 (expense) (60,958) (2,540,705) (141,515) before provision for income taxes & noncontrolling interest ,297,651 (2,549,577) 2,610,040 before noncontrolling interest ,297,651 (2,549,577) 2,610,040 Net loss (income) non-controlling interest , , Pea International, Inc ,400,799 (2,410,337) 2,610,484 - basic ,875,519 39,641,175 38,808,085 - fully diluted ,867, ,405,846 outstanding ,185,765 42,510,765 36,669,106 per common share - basic $0.03 $(0.06) $0.07 per common share - fully diluted $ $ As of March 1, 2017; 2 As of March 17, ; 3 As of March 9, 2015 Cash ,631,943 1,389,494 Cash restricted ,002,505 7,063,945 Accounts receivable ,269 16,742 assets , ,225 Total current assets ,015,351 8,724,406 Equipment , ,813 Software , ,097 Furniture & fixtures ,141 85,646 Leasehold improvements ,499 36,499 Total fixed assets ,006, ,055 depreciation , ,088 Fixed assets, net , ,967 Deposits ,551 3,551 Intangible assets, net ,550,044 1,264,151 Total assets ,871,707 10,264,075 Accounts payable & accrued liabilities , ,318 Customer card funding ,002,505 7,063,945 Legal settlement payable - current portion , ,475 Stocks payable - related parties , ,987 Notes payable , ,098 Total current liabilities ,218,755 8,744,823 Notes payable , Legal settlement payable - long-term portion ,183 Total long-term liabilities , ,183 Total liabilities ,246,647 9,084,006 Common stock ,186 42,511 capital ,726,173 6,579,508 Treasury stock at cost , ,000 (accumulated deficit) (3,799,613) (5,200,412) Total 3Pea International, Inc. s stockholders equity (deficit) ,819,746 1,271,607 Non-controlling interest (194,686) (91,538) equity (deficit) ,625,060 1,180,069 ABEONA THERAPEUTICS INC License revenues , , ,000 Royalties , , ,000 Total revenues ,000 1,040, ,000 development expenses ,655,000 4,715, ,000 expenses ,290,000 14,320,000 3,712,000 Depreciation & amortization , ,000 11,000 operations (23,881,000) (18,546,000) (3,131,000) Interest & miscellaneous income (expense).... 2,014,000 4,026,000 45,000 Interest & other expense ,000 6, ,000 Gain (loss) on change in fair value of derivative - preferred stock (23,110,000) (expense) ,008,000 4,020,000 (23,647,000).... (21,873,000) (14,526,000) (26,778,000) Less: preferred stock dividends ,875,000 allocable to common (29,653,000) - basic ,180,253 27,597,434 1,942,905 - diluted ,180,253 27,597,434 1,942,905 outstanding ,254,457 32,743,013 19,960,801 per share - basic..... $(0.64) $(0.53) $(15.26) per share - diluted.... $(0.64) $(0.53) $(15.26) , , ,900 1 Reclassified to conform with presentation; 2 Reclassified to conform with 2015 presentation; 3 As of March 30, 2017; 4 As of March 30, ; 5 As of March 31, 2015; 6 Approximately; 7 As of March 29, Cash & cash equivalents ,142,000 40,138,000 Receivables , ,000 current assets , ,000 Total current assets ,421,000 40,568,000 Equipment laboratory , ,000 Furniture & office equipment , ,000 Leasehold improvements ,000 33,000 cost , ,000 depreciation & amortization ,000 31,000 net , ,000 Licensed technology, net ,384,000 6,609,000 Goodwill ,466,000 32,466,000 Other assets ,000 62,000 Total assets ,058,000 80,055,000 Accounts payable ,694, ,000 Payable due Plasma Technologies, LLC ,000, Current portion of

3 April 11, 2017 MERGENT OTC UNLISTED NEWS 407 deferred revenue , ,000 Total current liabilities ,296,000 1,477,000 Contingent consideration liability ,591,000 Payable due licensor ,000,000 Long-term deferred revenue ,664,000 4,266,000 Total liabilities ,960,000 12,334,000 Common stock , ,000 capital ,168, ,993,000 (accumulated deficit) (332,473,000) (310,600,000) equity (deficit) ,098,000 67,721,000 ACACIA DIVERSIFIED HOLDINGS INC Revenues , Cost of goods sold , Depreciation expense , Gross profit , Employee compensation expenses , , ,767 expenses ,169, , ,193 Depreciation ,012 6,110 8,410 Total expenses ,814, Total costs & expenses , ,370 operation (1,742,119) (932,422) (540,370) Loss on sale of equipment to related party (42,987) Interest expense Interest income Interest income (expense) (14,666) (11,998) (expense) (42,995) (14,666) (11,998) before income taxes.. (1,785,114) (947,088) (552,368) operations (947,088) (552,368) Gain (loss) on operations , ,718 Gain on disposition of operations ,249, Net gain (loss) from operations ,475, , (1,785,114) 528,405 (151,650) shares outstanding-basic ,548,247 12,820,021 12,638,577 shares outstanding-diluted... 15,548,247 12,820,021 12,638,577 outstanding ,931,816 12,955,406 12,735,406 per share from operations-basic $(0.07) $(0.04) per share from operations-basic $0.12 $0.03 per share-basic $(0.11) $0.05 $(0.01) per share from operations-diluted $(0.07) $(0.04) per share from operation-diluted $0.12 $0.03 per share-diluted..... $(0.11) $0.05 $(0.01) Number of beneficial and prior years financials are for Co. s reverse acquistion on MariJ Group; 2 Restated to reflect the sales Citrus Extracts, Inc. and Acacia Transport Services, Inc. subsidiaries together with its Acacia Milling Services operations as operations; 3 Approximate Cash & cash equivalents , ,854 Account receivable , Prepaid expenses ,434 Raw materials , Finished goods (isolates, tinctures & capsules) , Inventories , current assets , Total current assets , ,288 Vehicles ,268 Computer equipment ,672 24,610 Furniture & fixtures Other equipment & software ,231 Website domain , Extraction & lab equipment , gross ,733 95,860 Less accumulated depreciation ,886 44,332 net ,847 51,528 Other assets Deposits Total assets , ,657 Accounts payable ,973 Accounts payable to vendors , Payroll taxes payable , Accrued bonuses to current CEO , Accrued severance compensation to former CEO , Accounts payable & accrued expenses , Payable to related party , Total current liabilities ,530 6,973 Total liabilities , Common stock ,932 12,955 capital ,393,539 12,034,270 (deficit) (3,120,218) (11,817,541) equity (deficit) , ,684 and prior years financials are for Co. s reverse acquistion on MariJ Group ACACIA DIVERSIFIED HOLDINGS INC Auditors, KWCO, PC, as it appeared in Co. s 10-K: "In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Acacia Diversified Holdings, Inc. as of December 31, and 2015, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31,, in conformity with accounting principles generally accepted in the United States of America. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the consolidated financial statements, the Company has suffered recurring losses from operations and its limited capital resources raise substantial doubt about its ability to continue as a going concern. Management s plans in regard to these matters are described in Note 3. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty." ACORN ENERGY INC Consolidated Income Statement, Years Ended Dec. 31 ($000): Revenues - projects ,970 Revenues - products ,682 Revenues - services ,908 Total revenues ,659 16,548 19,560 Cost of sales - projects ,352 Cost of sales - products ,099 Cost of sales - services Total cost of sales.... 5,134 10,381 12,922 Gross profit ,525 6,167 6,638 development expenses, net ,705 2,714 Selling, general & expenses ,651 9,632 12,023 Impairment of goodwill & intangibles ,773 Restructuring & related charges expenses ,578 11,337 16,804 (loss) (3,053) (5,170) (10,166) Interest income Interest expense Exchange gain (loss), net Gain on sale of interest in DSIT, net of transaction costs , before taxes on income - domestic... (142) (5,409) (8,204) before taxes on income - foreign (88) (2,091) before taxes on income (82) (5,497) (10,295) Current state & local income tax expense (benefit) Current foreign income tax expense (benefit) (50) 120 Total current income tax expense (benefit) (50) 121 Deferred foreign income tax expense (benefit) Total deferred income tax expense (benefit) Income tax expense (benefit) after income taxes.... (101) (5,706)...

4 408 MERGENT OTC UNLISTED NEWS April 11, 2017 Share of income in DSIT from operations (5,706) (10,459) operations, net of income taxes (286) (5,096) (19,140).... (119) (10,802) (29,599) Non-controlling interes share of loss - operations Non-controlling interes share of loss - operations ,407 Acorn Energy, Inc. shareholders (10,599) (27,145) shares outstanding-basic ,488 26,803 22,844 shares outstanding-diluted... 28,531 26,803 22,844 outstanding ,323 27,326 26,476 per share from operations-basic..... $0.02 $(0.21) $(0.46) per share from operations-basic..... $(0.01) $(0.19) $(0.73) per share-basic $0.01 $(0.40) $(1.19) per share from operations-diluted.... $0.02 $(0.21) $(0.46) per share from operations-diluted.... $(0.01) $(0.19) $(0.73) per share-diluted..... $0.01 $(0.40) $(1.19) Number of beneficial 3 4 4, , ,900 Foreign currency translation adjustments (36)... 1 Restated to reflect the operations of US Seismic Systems, Inc.; 2 Restated to reflect the cessation of GridSense as operations; 3 As is; 4 As of March 22, 2017; 5 As of March 25, ; 6 As of March 15, 2010; 7 Approximately; 8 As of March 24, 2015 Consolidated Balance Sheet, Years Ended Dec. 31 ($000): Cash & cash equivalents Restricted deposits ,172 Escrow deposit Accounts receivable, gross ,016 6,409 Allowance for doubtful accounts Accounts receivable, net ,005 6,389 Unbilled revenue ,849 Raw materials Work-in-process Finished goods Inventory, net Prepaid expenses & deposits Deferred costs Deferred taxes Funded severance assets Employee advances development participation receivable Other current assets Investment in DSIT , Current assets of operations ,079 Total current assets ,717 15,852 Computer hardware & software, cost ,296 depreciation & amortization-computer hardware & software ,202 Equipment, cost depreciation & amortization-equipment Leasehold improvements, cost depreciation & amortization-leasehold improvments net Severance assets ,558 Restricted deposit ,951 Goodwill Other assets Non-current assets of operations Total assets ,240 24,330 Short-term bank credit & current maturities of long-term bank debt ,916 Leap Tide Capital Partners III, LLC loan payable, net of discount ,900 Accounts payable ,346 Accrued payroll, payroll taxes & social benefits ,320 Deferred revenue ,149 5,251 Accrued expenses ,081 Taxes payable Warranty provision Restructuring liabilities Current liabilities of operations ,827 Total current liabilities ,186 16,820 Accrued severance ,984 Other long-term liabilities Due to Acorn director Due to DSIT , Long-term liabilities of operations Total long-term liabilities ,167 5,852 Common stock capital ,767 98,977 Warrants ,600 1,597 (accumulated deficit) (97,046) (97,191) Treasury stock, at cost ,036 3,036 comprehensive income (loss) (254) (262) Total Acorn Energy, Inc. shareholders equity (deficiency) , Non-controlling interests ,292 Total equity (deficit) ,887 1,658 1 Restated to reflect the operations of US Seismic Systems, Inc.; 2 Restated to reflect the cessation of GridSense as operations ACUCELA INC Consolidated Income Statement, Years Ended Dec. 31 ($000): 2014 Revenues from collaborations with a related party ,606 24,067 35,396 development expenses ,707 22,636 25,582 expenses ,895 27,987 10,002 Total expenses ,602 50,623 35,584 operations (35,996) (26,556) (188) Interest income ,408 1, Interest expense (expense), net (20) 37 (expense), net ,472 1, before income taxes.. (34,524) (25,459) 353 Federal income taxes benefit (expense) - current (2) (79) Federal income taxes benefit (expense) - deferred ,400 Federal income taxes benefit (expense) ,321 State income taxes benefit (expense) - current State income taxes benefit (expense) - deferred State income taxes benefit (expense) Income tax benefit (expense) , (34,525) (25,509) (2,006) common shareholders (34,525) (25,509) (2,006) - basic ,417 35,972 32,869 - diluted ,417 35,972 32,869 outstanding ,878 36,517 35,809 per share - basic..... $(0.92) $(0.71) $(0.06) per share - diluted.... $(0.92) $(0.71) $(0.06) , As is; 2 As of February 28, 2017; 3 As of March 3, ; 4 As of March 19, 2015 Consolidated Balance Sheet, Years Ended Dec. 31 ($000): Cash & cash equivalents ,949 5,088 Investments , ,922 Accounts receivable from collaborations ,055 6,140 current assets ,950 2,051 Total current assets , ,201

5 April 11, 2017 MERGENT OTC UNLISTED NEWS 409 Laboratory & computer equipment ,921 2,981 Leasehold improvements ,423 1,423 Office furniture & equipment gross ,841 4,770 depreciation & amortization ,071 3,850 net Long-term investments ,975 54,515 Other assets Total assets , ,950 Accounts payable Accrued liabilities ,726 3,138 Accrued compensation ,295 2,457 Deferred revenue from collaborations ,467 Deferred rent & lease incentives Total current liabilities ,613 8,412 Long-term deferred rent, lease incentives & others ,104 Total long-term liabilities ,104 Common stock , ,984 comprehensive income (loss) (132) (575) (accumulated deficit) (65,500) (30,975) Total shareholders equity (deficit) , ,434 - diluted ,870,000 10,796, ,779,000 outstanding ,834,000 11,801, ,770,000 Earnings (loss) per share - basic $(0.62) $(0.46) 2 $(1.35) Earnings (loss) per share - diluted $(0.62) $(0.46) 2 $(1.35) Reclassified to conform with 2015 presentation; 2 Adjusted 1 Reclassified to conform with presentation; 2 Discount for 1-for-5 stock split, August 28, 2015; 3 Approximately; 4 As - Long-term debt: $98,000; 3 Debt issuance cost - Long-term of January 31, 2017; 5 As of February 29, ; 6 As of February debt: $193,000; 4 Discount - Long-term debt: $193,000; 5 Debt 27, 2015 issuance cost - Long-term debt: $97,000 Cash & cash equivalents ,681, Cash & cash equivalents - restricted ,500,000 2,485,000 Marketable securities ,837,000 Trade accounts receivable, gross , ,000 Allowance for doubtful accounts ,000 91,000 Trade accounts receivable ,000 42,000 Collaboration revenue receivable ,000 36,000 Royalty receivable ,000 5,000 Accrued investment income ,000 Raw materials , Finished goods , ,000 Less: inventory reserve - 1 Reclassified to conform with presentation finished goods ,000 70,000 Inventories , ,000 ACURA PHARMACEUTICALS INC current assets , ,000 Total current assets ,910,000 14,135,000 Building & improvements ,273,000 1,265, Scientific equipment , ,000 Computer hardware & License fee revenue.. 3,500,000 5,250, ,000 software , ,000 Milestone revenue ,500, Machinery & equipment , ,000 Collaboration Land & improvements , ,000 revenue , , Other personal property ,000 70,000 Royalty revenue ,000 5,000 4,000 Office equipment ,000 27,000 Product sales, net , , ,000 Property, plant & Total revenues ,464,000 8,587, ,000 equipment, gross ,807,000 2,754,000 Cost of sales (excluding depreciation & inventory amortization ,741,000 write-down) , , ,000 Less: impairment reserve (82,000)... Inventory reserve expense for depreciation ,858, write-downs , , ,000 Property, plant & equipment, net ,000 1,013,000 development expense. 4,028,000 2,608,000 4,582,000 Intangible asset, gross ,000,000 2,000,000 Selling, marketing, Less: Accumulated general & amortization - intangible asset , ,000 expenses ,516,000 8,994,000 7,940,000 Intangible asset ,431,000 1,638,000 Other assets ,000 expenses ,021,000 12,588,000 12,950,000 Total assets ,208,000 16,961,000 Accounts payable , ,000 (loss) (6,557,000) (4,001,000) (12,199,000) Professional services , ,000 Investment income Other fees & services ,000 64,000 (loss) , , ,000 Payroll, payroll taxes & Interest expense ,000 1,157,000 1,212,000 benefits , ,000 Gain on sales of Clinical & regulatory marketable services ,000 92,000 securities ,000 3,000 4,000 Marketing, advertising, & promotion , ,000 (expense) (831,000) (988,000) (1,010,000) Property taxes ,000 15,000 Franchise taxes ,000 6,000 before income tax.... (7,388,000) (4,989,000) (13,209,000) Other current liabilities ,000 45, (7,388,000) (4,989,000) (13,209,000) Sales returns liability , ,000 Current maturities of long-term debt ,376,000 2,320,000 - basic ,870,000 10,796, ,779,000 Total current liabilities ,487,000 3,244,000 Long-term debt, net Long-term portion of 2 3 2,979, ,430,000 accrued interest , ,000 Total liabilities ,025,000 9,061,000 Common stock , ,000 capital ,763, ,157,000 (accumulated deficit) (374,698,000) (367,310,000) comprehensive income (loss) (65,000) equity (deficiency) ,183,000 7,900,000 ACURA PHARMACEUTICALS INC Auditors, BDO USA, LLP, as it appeared in Co. s 10-K: "In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Acura Pharmaceuticals Inc. at December 31, and 2015, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and has not generated positive cash flows from operations. These factors raise substantial doubt about the Company s ability to continue as a going concern. Management s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty." ADAMIS PHARMACEUTICALS CORP Revenue, net ,473, Cost of goods sold... 4,853, Gross profit ,620, Selling, general & expenses ,127,555 9,007,289 4,556,291 development ,697,136 4,843,139 3,545,475 operations (25,204,377) (13,850,428) (8,101,766) Interest expense , ,286 Interest income , Change in fair value of warrant liability ,049, ,898 (1,053,256) Change in fair value of warrant derivative liabilities ,141 (155,467) 64,953 (expense) ,192, ,431 (1,214,589) before income taxes.. (24,012,017) (13,571,997)... Income tax expense (benefit) (4,574,765) (19,437,252) (13,571,997) (9,316,355) Deemed dividend on preferred stock ,374, applicable to common stockholders (20,811,481) (13,571,997)... - basic ,500,827 13,275,847 10,526,618 - diluted ,500,827 13,436,683 10,526,618 outstanding ,991,543 13,431,659 10,651,940

6 410 MERGENT OTC UNLISTED NEWS April 11, 2017 per share - basic..... $(1.19) $(1.02) $(0.89) per share - diluted.... $(1.19) $(1.03) $(0.89) Reclassified to conform with presentation; 2 For 9 months due to fiscal year end change; 3 Approximately Cash ,090,651 4,080,648 Restricted cash ,005, Accounts receivable, gross , Provision for bad debt , Accounts receivable, net , Finished goods , Raw materials , Devices , Inventories , Prepaid insurance ,765 27,923 Other prepaid expenses , Other current assets ,500 42,606 Total current assets ,070,239 4,151,633 Security deposits ,500 85,000 Intangible assets, net ,136,044 7,766,960 Goodwill ,640, Land , Buildings ,040, Machinery & equipment ,393,226 97,100 Furniture & fixtures , Automobile , Leasehold improvements , gross ,316,288 97,100 depreciation ,552 38,840 Construction work in progress - equipment , Fixed assets, net ,897,007 58,260 Total assets ,786,412 12,061,853 Accounts payable ,150, ,794 Deferred revenue , Accrued commissions , Accrued expenses ,865 82,340 Accrued PTO ,709 77,006 Accrued salaries , Accrued sales taxes , Accrued sate tax , Deferred rent ,223 54,690 Health insurance claims payable , Accrued bonuses , ,274 Bank loans - working capital line of credit ,864, Bank loans - building & equipment, current portion , Warrants, at fair value ,174,312 Warrant derivative liabilities, at fair value ,404 Total current liabilities ,610,924 2,747,820 Deferred tax liability, net , Building & equipment loans, net of current portion ,067, Total liabilities ,506,545 2,747,820 Series A convertible preferred stock Common stock ,230 1,374 capital ,741,412 78,339,143 (accumulated deficit) (88,458,608) (69,021,356) Treasury stock, at cost ,229 5,229 equity (deficit) ,279,867 9,314,033 1 Reclassified to conform with presentation ADAMIS PHARMACEUTICALS CORP. Auditors, Mayer Hoffman McCann P.C., as it appeared in Co. s 10-K: "In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Adamis Pharmaceuticals Corporation and Subsidiaries as of December 31, and 2015, and the results of their operations and their cash flows for the years ended December 31, and 2015, in conformity with U.S. generally accepted accounting principles. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has incurred recurring losses from operations, and is dependent on additional financing to fund operations. These conditions raise substantial doubt about the Company s ability to continue as a going concern. Management s plans in regard to these matters are described in Note 2 to the consolidated financial statements. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty." ADESTO TECHNOLOGIES CORP Consolidated Income Statement, Years Ended Dec. 31 ($000): Revenue ,968 43,259 41,465 Cost of revenue ,618 24,775 25,532 Gross profit ,350 18,484 15,933 development ,896 12,795 14,410 Sales & marketing expenses ,026 8,345 7,211 expenses ,693 3,978 2,356 Gain from settlement with former foundry supplier , expenses ,653 25,118 23,977 operations (10,303) (6,634) (8,044) Interest expense, net ,275 1, (expense), net (50) (695) 114 (expense), net (1,325) (1,810) (750) Income before income taxes - United States (11,843) (9,232) (7,885) Income before income taxes - Foreign (909) before provision for income taxes..... (11,628) (8,444) (8,794) Current state income taxes Current foreign income taxes (19) (38) 123 Current income taxes (17) (35) 126 Deferred federal income taxes (26) 14 Deferred income taxes (26) 14 Provision for income taxes (16) (61) (11,612) (8,383) (8,934) - basic ,086 3, diluted ,086 3, outstanding ,494 14, ,465 per share - basic..... $(0.77) $(2.79) $(16.48) per share - diluted.... $(0.77) $(2.79) $(16.48) Foreign currency translation adjustments (84) (143) 63 1 Reclassified to conform with presentation; 2 Adjusted for 1-for -33 stock split, October 1, 2015; 3 As is; 4 As of June 30, 2015; 5 As of March 8, 2017; 6 As of March 27, Consolidated Balance Sheet, Years Ended Dec. 31 ($000): Cash & cash equivalents ,719 23,089 Accounts receivable, gross ,800 10,936 Less: allwance for ship from stock & debits (SSDs) ,689 4,400 Accounts receivable, net ,111 6,536 Raw materials ,149 Work in process ,793 4,844 Finished goods ,177 1,375 Inventories ,182 7,368 Prepaid expenses ,155 Foreign research credit receivable ,063 Other current assets Total current assets ,579 39,334 Machinery & equipment ,351 6,627 Furniture & fixtures Leasehold improvements , Computer software Construction in progress , at cost ,446 7,565 depreciation & amortization ,484 6,656 net , Intangible assets, net ,324 9,559 Other non-current assets Goodwill Total assets ,183 49,938 Accounts payable ,167 9,680 Income taxes payable Accrued compensation & benefits , Accrued sales commissions payable Accrued manufacturing expenses Deferred rent Liabilities to certain customers Other accrued liabilities Term loan ,466 5,606 Total current liabilities ,408 17,644 Line of credit , Term loan ,775 7,814 Deferred rent, non-current , Deferred tax liability, non-current Total liabilities ,818 25,459 Common stock capital , ,167 comprehensive income (loss) (230) (146)

7 April 11, 2017 MERGENT OTC UNLISTED NEWS 411 (accumulated deficit) (94,156) (82,544) equity (deficit) ,365 24,479 1 Reclassified to conform with presentation ADVANCED BIOMEDICAL TECHNOLOGIES, INC. Earnings, 3 mos. to Jan 31(Consol. $): 2017 Cost & expenses , , (88,588) (124,058) Interest income (expense), net (3,725) (3,302) Net before taxes (154,113) (190,515) Net income (154,113) (190,515) Balance for common (154,113) (190,515) Earnings common share Common Shares: Full Diluted ,124,850 65,570,502 Year-end ,124,850 66,874,850 Consolidated Balance Sheet Items, as of ($): Assets: 2017 Cash & equivalents ,030 Current assets ,557 Net property & equip ,714 Total assets ,271 Liabilities: Current liabilities ,553,356 Stockholders equity (4,454,085) Net current assets (4,520,799) ADVANCED MEDICAL ISOTOPE CORP Consulting revenues.. 8,108 24,108 24,108 Cost of materials ,104 Sales & marketing expenses , ,300 Depreciation & amortization expense ,947 5,672 11,992 Professional fees ,068, , ,797 Stock options granted & warrant expense ,748 Stock based compensation ,324 80, Payroll expenses , , ,625 development , ,650 44,268 expenses , , ,295 expenses ,444,578 2,065,371 1,979,129 (loss) (4,436,470) (2,041,263) (1,955,021) Interest expense ,259,467 3,196,153 2,458,322 Gain (loss) on settlement of debt.... 3,108,342 3,562,067 (638,491) Grant income ,010 21, Loss (gain) on derivative liability ,244,353 (7,887,025) 10,566,120 Loss (gain) on warrant modification ,490,752 Loss on impaired assets , Non-operating income (expense), net (5,418,425) 8,273,949 (16,153,685) before income taxes.. (9,854,895) 6,232,686 (18,108,706).... (9,854,895) 6,232,686 (18,108,706) - basic ,497, ,505,467 3,192,692 outstanding ,743, ,969, ,053,826 per share - basic..... $(0.46) 3 $0.34 $(5.70) Reclassified to conform with presentation; 2 Reclassified to conform with 2015 presentation; 3 Adjusted for 1-for-100 stock split, October 11, ; 4 Shares increased due to the effect of common stock issued for exercise of options and warrants, settlement of debt, and conversion of preferred stock; 5 Shares increased due to the effect of issuance for debt conversion, cash and exercise of warrants, loan fees on convertible debt and services; 6 Approximately; 7 As of March 6, 2017; 8 As of May 13, ; 9 As of April 10, 2015 Cash , ,032 Prepaid expenses ,990 26,211 Inventory ,475 Total current assets , ,718 Production equipment ,182 1,938,532 Building ,772 Leasehold improvements ,235 Office equipment ,594 32,769 Fixed assets, gross ,776 2,421,308 depreciation ,303 2,416,888 Fixed assets, net of accumulated depreciation ,473 4,420 Patents & intellectual property ,482 Deposits Total assets , ,264 Accounts payable & accrued expenses ,137,086 1,182,112 Related party accounts payable , ,647 Accrued interest payable , ,246 Payroll liabilities payable , ,900 Convertible notes payable, net ,508 1,788,384 Derivative liability ,532 4,235,016 Related party promissory note ,195 1,280,450 Liability for lack authorized shares ,091 Total current liabilities ,062,296 9,968,846 Total liabilities ,062,296 9,968,846 Preferred stock ,144,571 4,617,052 Total mezzanine equity ,144,571 4,617,052 Common stock ,744 19,969 Paid in capital ,672,825 33,662,942 (accumulated deficit) (57,869,440) (48,014,545) equity (deficit) (17,164,871) (14,331,634) 1 Reclassified to conform with presentation ADVANCED VOICE RECOGNITION SYSTEMS INC Compensation ,928 1,577 45,400 Professional fees ,558 52,300 67,508 Office expense ,397 24,307 21,791 Travel expense ,192 Other operating expenses ,689 1,528 1,095 expenses ,892 80, ,986 operations (65,892) (80,416) (136,986) Interest expense ,954 7,591 2,327 Net other income (expense) (10,954) (7,591) (2,327) before income taxes.. (76,846) (88,007) (139,313) before extraordinary items... (76,846) (88,007) (76,846) (88,007) (139,313) shares outstanding-basic ,639, ,054, ,635,049 shares outstanding-diluted ,639, ,054, ,635,049 outstanding ,395, ,595, ,195,268 per share-basic $0.00 $0.00 $0.00 per share-diluted..... $0.00 $0.00 $ Reclassified to conform with presentation; 2 Reclassified to conform with 2015 presentation; 3 Approximate Cash ,454 8,997 Total current assets ,454 8,997 Computer equipment ,627 6,627 Computer software ,640 3,640 Computer software & equipment, gross ,267 10,267 depreciation ,267 9,530 Computer software & equipment, net Patent, net ,658 80,112 Deferred costs ,485 1,485 Total intangible assets ,143 81,597 Total assets ,597 91,331 Accounts payable ,393 92,999 Payroll , ,383 Note payable AIP ,935 19,935 Accrued interest ,987 1,994 Indebtedness to related parties Total current liabilities , ,911 Common stock , ,595 capital ,741,773 7,702,247 (accumulated deficit) (8,190,269) (8,113,423) equity (deficit) (218,101) (186,580) 1 Reclassified to conform with presentation ADVANCED VOICE RECOGNITION SYSTEMS INC The following is an excerpt from the Report of Independent Auditors, B F Borgers CPA PC, as it appeared in Co. s 10-K: "In our opinion, the financial statement referred to above present fairly, in all material respects, the financial position of Advanced Voice Recognition Systems, Inc., as of December 31,, and the results of its operations and its cash flows for the year then ended, in conformity with generally accepted accounting principles in the United States of America. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and has a significant accumulated deficit. In addition, the Company continues to experience negative cash flows from operations. These factors raise substantial doubt about the Company s ability to continue as a going concern. Management s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty." AEROPOSTALE INC